These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32564903)

  • 1. Hematolymphoid neoplasms with a plasma cell phenotype.
    Rosado F; Guo L; Fuda F
    Semin Diagn Pathol; 2020 Nov; 37(6):268-272. PubMed ID: 32564903
    [No Abstract]   [Full Text] [Related]  

  • 2. Flow cytometric immunophenotyping for hematologic neoplasms.
    Craig FE; Foon KA
    Blood; 2008 Apr; 111(8):3941-67. PubMed ID: 18198345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodality Technologies in the Assessment of Hematolymphoid Neoplasms.
    Li S; Jaye DL; Bradley KT; Zhang L; Saxe D; Deeb G; Hill CE; Mann KP
    Arch Pathol Lab Med; 2017 Mar; 141(3):341-354. PubMed ID: 28055240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometry immunophenotyping of hematolymphoid neoplasia.
    Calvo KR; McCoy CS; Stetler-Stevenson M
    Methods Mol Biol; 2011; 699():295-316. PubMed ID: 21116989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematolymphoid Malignancies Presenting with Spinal Epidural Mass and Spinal Cord Compression: A Case Series with Rare Entities.
    Pandey S; Gokden M; Kazemi NJ; Post GR
    Ann Clin Lab Sci; 2019 Nov; 49(6):818-828. PubMed ID: 31882434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report of proceedings of the national meeting on "Guidelines for Immunophenotyping of Hematolymphoid Neoplasms by Flow Cytometry".
    Gujral S; Subramanian PG; Patkar N; Badrinath Y; Kumar A; Tembhare P; Vazifdar A; Khodaiji S; Madkaikar M; Ghosh K; Yargop M; Dasgupta A
    Indian J Pathol Microbiol; 2008; 51(2):161-6. PubMed ID: 18603672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Hematolymphoid Tumours.
    Brown NA; Elenitoba-Johnson KS
    Head Neck Pathol; 2017 Mar; 11(1):96-109. PubMed ID: 28247223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms.
    O'Connell FP; Pinkus JL; Pinkus GS
    Am J Clin Pathol; 2004 Feb; 121(2):254-63. PubMed ID: 14983940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Pathologic Spectrum of DDX41-Mutated Hematolymphoid Neoplasms.
    Goyal T; Tu ZJ; Wang Z; Cook JR
    Am J Clin Pathol; 2021 Oct; 156(5):829-838. PubMed ID: 33929502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematolymphoid neoplasms: World Health Organization versus rest of the world.
    Gujral S
    Leukemia; 2009 May; 23(5):978. PubMed ID: 19020544
    [No Abstract]   [Full Text] [Related]  

  • 11. The rate of MEFV gene mutations in hematolymphoid neoplasms.
    Celik S; Erikci AA; Tunca Y; Sayan O; Terekeci HM; Umur EE; Torun D; Tangi F; Top C; Oktenli C
    Int J Immunogenet; 2010 Oct; 37(5):387-91. PubMed ID: 20518828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2006 Bethesda International Consensus Conference on Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasia.
    Stetler-Stevenson M; Davis B; Wood B; Braylan R
    Cytometry B Clin Cytom; 2007; 72 Suppl 1():S3. PubMed ID: 17630651
    [No Abstract]   [Full Text] [Related]  

  • 13. International consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia.
    Wilson WH
    Cytometry B Clin Cytom; 2007; 72 Suppl 1():S2. PubMed ID: 17803186
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous tumors as the initial presentation of non-T, non-B, nonmyeloid CD4+ CD56+ hematolymphoid malignancy in an adolescent boy.
    Fass J; Tichy EH; Kraus EW; Herrick JL; Ehsan A; Peterson J; Grimwood RE
    Pediatr Dermatol; 2005; 22(1):19-22. PubMed ID: 15660891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards a molecular classification of hematolymphoid neoplasms: where are we now? Where are we going?
    Hsi ED
    J Histochem Cytochem; 2001 Oct; 49(10):1323-4. PubMed ID: 11561018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunophenotype of Spontaneous Hematolymphoid Tumors Occurring in Young and Aging Female CD-1 Mice. [Corrected].
    Rehg JE; Rahija R; Bush D; Bradley A; Ward JM
    Toxicol Pathol; 2015 Oct; 43(7):1025-34. PubMed ID: 26224701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Section II: hematolymphoid malignancies.
    Zhang L; Rossi MR; Fisher KE
    Curr Probl Cancer; 2014; 38(5):159-74. PubMed ID: 25239561
    [No Abstract]   [Full Text] [Related]  

  • 18. Limited Tissue Biopsies and Hematolymphoid Neoplasms.
    Ingersoll KF; Zhao Y; Harrison GP; Li Y; Yang LH; Wang E
    Am J Clin Pathol; 2019 Nov; 152(6):782-798. PubMed ID: 31365922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications.
    Davis BH; Holden JT; Bene MC; Borowitz MJ; Braylan RC; Cornfield D; Gorczyca W; Lee R; Maiese R; Orfao A; Wells D; Wood BL; Stetler-Stevenson M
    Cytometry B Clin Cytom; 2007; 72 Suppl 1():S5-13. PubMed ID: 17803188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An unexpected association of hematologic malignancies.
    Athanase N; Frébet E
    Blood; 2018 Oct; 132(14):1545. PubMed ID: 30287471
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.